Back to the main directory
Company Analysis / Equity
- Poor 1Q18 results, distorted by provisions and forex by Bankinter S.A.
- VIPS: Benefiting From Traffic Support From 2Q18 Onward by T.H. Capital
- EA will benefit from its renewed focus on improved game quality and the gamer experience. by Morningstar
- Emera Energy and Florida Drive Solid 1Q Results by Morningstar
- AKD STOCK SMART, May 11, 2018 by AKD Securities Limited
- TDK Expects Robust Revenue Growth on Passive Components, Sensors, and Batteries; Shares Undervalued by Morningstar
- Strong Start to the Year for Pilgrim’s Pride as Its Strategy Delivers Benefits; Shares Attractive by Morningstar
- Tough Macro Equipment Conditions Continue for Ritchie in 1Q by Morningstar
- Raising Our BMW FVE to EUR 117 From EUR 110; Initiating ADR Coverage With $46 FVE by Morningstar
- Growing global demand for BMW premium-priced products supports solid economic profit. by Morningstar
- Lundbeck's Robust 1Q Results Overshadowed by the Storms Ahead; Shares Overvalued by Morningstar
- Trump’s Drug Plan Looks to Modestly Lower Drug Prices, Keeping Big Pharma and Biotech Moats Intact by Morningstar
- Trump’s Drug Plan Looks to Modestly Lower Drug Prices, Keeping Big Pharma and Biotech Moats Intact by Morningstar
- Trump’s Drug Plan Looks to Modestly Lower Drug Prices, Keeping Big Pharma and Biotech Moats Intact by Morningstar
- Trump’s Drug Plan Looks to Modestly Lower Drug Prices, Keeping Big Pharma and Biotech Moats Intact by Morningstar
- Trump’s Drug Plan Looks to Modestly Lower Drug Prices, Keeping Big Pharma and Biotech Moats Intact by Morningstar
- Trump’s Drug Plan Looks to Modestly Lower Drug Prices, Keeping Big Pharma and Biotech Moats Intact by Morningstar
- Trump’s Drug Plan Looks to Modestly Lower Drug Prices, Keeping Big Pharma and Biotech Moats Intact by Morningstar
- Trump’s Drug Plan Looks to Modestly Lower Drug Prices, Keeping Big Pharma and Biotech Moats Intact by Morningstar
- Trump’s Drug Plan Looks to Modestly Lower Drug Prices, Keeping Big Pharma and Biotech Moats Intact by Morningstar
- Trump’s Drug Plan Looks to Modestly Lower Drug Prices, Keeping Big Pharma and Biotech Moats Intact by Morningstar
- Trump’s Drug Plan Looks to Modestly Lower Drug Prices, Keeping Big Pharma and Biotech Moats Intact by Morningstar
- Trump’s Drug Plan Looks to Modestly Lower Drug Prices, Keeping Big Pharma and Biotech Moats Intact by Morningstar
- Trump’s Drug Plan Looks to Modestly Lower Drug Prices, Keeping Big Pharma and Biotech Moats Intact by Morningstar
- The More Things Change the More They Stay The Same: Takeaways From Teleflex's Investor Day by Morningstar
- MRL: Mixed set of 1Q18 results by Bankinter S.A.
- Q1/18 mit gutem Start – Akquisitionen liefern by EQUITS GmbH
- Initiating Coverage of TransUnion With a Wide Moat Rating by Morningstar
- Emera's mostly regulated business mix drives capital growth opportunities. by Morningstar
- Smart Sand's Shares Drop on 1Q Results, but Our FVE Is Unchanged by Morningstar
- Weekly Market Wrap - 11 May 2018 by Vetiva Capital Management
- Tough Macro Equipment Conditions Continue for Ritchie in 1Q by Morningstar
- We’re Slightly Lowering CRH’s FVE After Re-Evaluating Several Assumptions by Morningstar
- We’re Slightly Lowering CRH’s FVE After Re-Evaluating Several Assumptions by Morningstar
- Power Gets a Pop From Sagard in 1Q by Morningstar
- Trump’s Drug Plan Looks to Modestly Lower Drug Prices, Keeping Big Pharma and Biotech Moats Intact by Morningstar
- Trump’s Drug Plan Looks to Modestly Lower Drug Prices, Keeping Big Pharma and Biotech Moats Intact by Morningstar
- Trump’s Drug Plan Looks to Modestly Lower Drug Prices, Keeping Big Pharma and Biotech Moats Intact by Morningstar
- Trump’s Drug Plan Looks to Modestly Lower Drug Prices, Keeping Big Pharma and Biotech Moats Intact by Morningstar
- Trump’s Drug Plan Looks to Modestly Lower Drug Prices, Keeping Big Pharma and Biotech Moats Intact by Morningstar
- Trump’s Drug Plan Looks to Modestly Lower Drug Prices, Keeping Big Pharma and Biotech Moats Intact by Morningstar
- Trump’s Drug Plan Looks to Modestly Lower Drug Prices, Keeping Big Pharma and Biotech Moats Intact by Morningstar
- Trump’s Drug Plan Looks to Modestly Lower Drug Prices, Keeping Big Pharma and Biotech Moats Intact by Morningstar
- Trump’s Drug Plan Looks to Modestly Lower Drug Prices, Keeping Big Pharma and Biotech Moats Intact by Morningstar
- Trump’s Drug Plan Looks to Modestly Lower Drug Prices, Keeping Big Pharma and Biotech Moats Intact by Morningstar
- Trump’s Drug Plan Looks to Modestly Lower Drug Prices, Keeping Big Pharma and Biotech Moats Intact by Morningstar
- Trump’s Drug Plan Looks to Modestly Lower Drug Prices, Keeping Big Pharma and Biotech Moats Intact by Morningstar
- Trump’s Drug Plan Looks to Modestly Lower Drug Prices, Keeping Big Pharma and Biotech Moats Intact by Morningstar
- Trump’s Drug Plan Looks to Modestly Lower Drug Prices, Keeping Big Pharma and Biotech Moats Intact by Morningstar
- As Shares Fall, Thomson Reuters' Buyback Creates Value by Morningstar